These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 8402670

  • 1. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P.
    Cancer Res; 1993 Oct 15; 53(20):4837-42. PubMed ID: 8402670
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
    Chambers SK, Davis CA, Chambers JT, Schwartz PE, Lorber MI, Hschumacher RE.
    Clin Cancer Res; 1996 Oct 15; 2(10):1699-704. PubMed ID: 9816119
    [Abstract] [Full Text] [Related]

  • 3. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 4. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J, Limacher JM, Levêque D, Duclos B, Dufour P, Bergerat JP, Methlin G.
    Bull Cancer; 1997 Jun 01; 84(6):603-8. PubMed ID: 9295863
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I, Bench K, Beijnen JH, Bruntsch U, Cavalli F, de Jong J, Groot Y, van Tellingen O, Wanders J, Sessa C.
    Clin Cancer Res; 1996 Oct 01; 2(10):1717-23. PubMed ID: 9816122
    [Abstract] [Full Text] [Related]

  • 7. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N.
    Cancer Res; 1991 Mar 01; 51(5):1472-7. PubMed ID: 1997185
    [Abstract] [Full Text] [Related]

  • 8. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C, Fabbro M.
    Clin Cancer Res; 2000 Jan 01; 6(1):57-63. PubMed ID: 10656432
    [Abstract] [Full Text] [Related]

  • 9. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG.
    Cancer Res; 1993 Mar 01; 53(5):1032-6. PubMed ID: 8439950
    [Abstract] [Full Text] [Related]

  • 10. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D, Vassal G, Pondarré C, Bonnay M, Benhamou E, Couanet D, Plantaz D, Hartmann O.
    Bone Marrow Transplant; 1996 Apr 01; 17(4):485-9. PubMed ID: 8722343
    [Abstract] [Full Text] [Related]

  • 11. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK, Hwang WS.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(5):847-53. PubMed ID: 17609947
    [Abstract] [Full Text] [Related]

  • 12. High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial.
    Stiff PJ, Bayer R, Tan S, Camarda M, Sosman J, Peace D, Kinch L, Rad N, Loutfi S.
    Clin Cancer Res; 1995 Dec 01; 1(12):1495-502. PubMed ID: 9815949
    [Abstract] [Full Text] [Related]

  • 13. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.
    Remick SC, Grem JL, Fischer PH, Tutsch KD, Alberti DB, Nieting LM, Tombes MB, Bruggink J, Willson JK, Trump DL.
    Cancer Res; 1990 May 01; 50(9):2667-72. PubMed ID: 2328492
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
    Lyass O, Hubert A, Gabizon AA.
    Clin Cancer Res; 2001 Oct 01; 7(10):3040-6. PubMed ID: 11595693
    [Abstract] [Full Text] [Related]

  • 16. A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.
    Duska LR, Penson R, Supko JG, Finkelstein DM, Makastorsis T, Gallagher J, Borden K, Goodman A, Fuller AF, Nikrui N, Seiden MV.
    Clin Cancer Res; 1999 Jun 01; 5(6):1299-305. PubMed ID: 10389912
    [Abstract] [Full Text] [Related]

  • 17. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Jun 01; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 18. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
    Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.
    Bone Marrow Transplant; 2001 Feb 01; 27(3):269-78. PubMed ID: 11277174
    [Abstract] [Full Text] [Related]

  • 19. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF, Garrido MJ, Segura C, Cendrós JM, Principe P, Peraire C, Obach R.
    Cancer Chemother Pharmacol; 2006 Jun 01; 57(6):727-35. PubMed ID: 16261364
    [Abstract] [Full Text] [Related]

  • 20. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg ME, Luyten GP, de Leeuw K, de Boer-Dennert M, Wissel PS, Jewell RC, Paul EM, Purvis NB, Verweij J.
    Cancer Chemother Pharmacol; 2005 Jan 01; 55(1):91-9. PubMed ID: 15565444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.